

PRODUCT INFORMATION



MDMB-4en-PINACA-d₄

Item No. 36754

Formal Name: 3-methyl-N-[[1-(4-penten-1-yl)-1H-indazol-3-yl]carbonyl-d₄]-L-valine, methyl ester

Synonyms: MDMB-PENINACA-d₄, MDMB-PINACA N1-pentyl-4-en isomer-d₄

MF: C₂₀H₂₃D₄N₃O₃

FW: 361.5


Chemical Purity: ≥98% (MDMB-4en-PINACA)

Deuterium Incorporation: ≥99% deuterated forms (d₁-d₄); ≤1% d₀

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Description

MDMB-4en-PINACA-d₄ (Item No. 36754) is intended for use as an internal standard for the quantification of MDMB-4en-PINACA (Item Nos. 30761 | 26097) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

MDMB-4en-PINACA is categorized as a synthetic cannabinoid.¹ It substitutes for Δ⁹-THC (Item Nos. ISO60157 | 9003771 | 12068) in a drug discrimination test and induces hypothermia in mice.² MDMB-4en-PINACA has been associated with overdose and found in samples seized by law enforcement.^{3,4} MDMB-4en-PINACA-d₄ is regulated as a Schedule I compound in the United States. This product is intended for research and forensic applications.

Reference

1. Cannaert, A., Sparkes, E., Pike, E., *et al.* Synthesis and *in vitro* cannabinoid receptor 1 activity of recently detected synthetic cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA. *ACS Chem. Neurosci.* **11**(24), 4434-4446 (2020).
2. Marusich, J.A., Gamage, T.F., Zhang, Y., *et al.* In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists. *Pharmacol. Biochem. Behav.* **220**, 173467 (2022).
3. Manini, A.F., Krotulski, A.J., Schimmel, J., *et al.* Respiratory failure in confirmed synthetic cannabinoid overdose. *Clin. Toxicol. (Phila)* **60**(4), 524-526 (2022).
4. Rodrigues, T.B., Souza, M.P., de Melo Barbosa, L., *et al.* Synthetic cannabinoid receptor agonists profile in infused papers seized in Brazilian prisons. *Forensic Toxicol.* **40**(1), 119-124 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/18/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM